<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291187</url>
  </required_header>
  <id_info>
    <org_study_id>VP-VEC-162-3101</org_study_id>
    <nct_id>NCT00291187</nct_id>
  </id_info>
  <brief_title>VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 and Matching Placebo in Healthy Male and Female Subjects With Induced Transient Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of VEC-162 compared to
      placebo to improve sleep parameters in a model of insomnia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Improvement of Latency to Persistent Sleep (LPS)</measure>
    <time_frame>Night 1</time_frame>
    <description>The average improvement in Latency to persistent sleep (the number of minutes between Lights Off and the onset of at least 10 minutes of persistent sleep, as measured by polysomnography) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Improvement of Wake After Sleep Onset (WASO)</measure>
    <time_frame>Night 1</time_frame>
    <description>The average improvement of wake after sleep onset (time spent awake between onset of sleep and lights on, determined by PSG) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">411</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Take orally 30 minutes prior to bedtime.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg VEC-162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg taken orally 30 minutes prior to bedtime.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg VEC-162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg taken orally 30 minutes prior to bedtime.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg VEC-162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg taken orally 30 minutes prior to bedtime.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mg VEC-162</intervention_name>
    <description>20 mg VEC-162</description>
    <arm_group_label>20 mg VEC-162</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg VEC-162</intervention_name>
    <description>50 mg VEC-162</description>
    <arm_group_label>50 mg VEC-162</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg VEC-162</intervention_name>
    <description>100 mg VEC-162</description>
    <arm_group_label>100 mg VEC-162</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects with no medical, psychiatric or current sleep disorders.

          -  Subject must sign a written consent form.

        Exclusion Criteria:

          -  Recent history of night shift work or jet lag.

          -  Prior experience sleeping in a sleep lab environment.

          -  History of sleep disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vanda Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Vanda Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanda Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2006</study_first_submitted>
  <study_first_submitted_qc>February 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2006</study_first_posted>
  <results_first_submitted>February 28, 2014</results_first_submitted>
  <results_first_submitted_qc>October 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 15, 2014</results_first_posted>
  <last_update_submitted>October 8, 2014</last_update_submitted>
  <last_update_submitted_qc>October 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place at 20 US sites. The first subject was screened on February 9th 2006, the first subject enrolled on March 10th, 2006, and the last subject completed on August 21st 2006.</recruitment_details>
      <pre_assignment_details>Prior to treatment assignment, subjects were instructed to start a sleep schedule that required staying in bed and trying to sleep for at least 8 hours per night.
One subject randomized to VEC-162 50 mg was non-compliant for sleep schedule. Subject was discontinued on Day 1 prior to study drug administration.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>taken orally 30 minutes prior to bedtime</description>
        </group>
        <group group_id="P2">
          <title>VEC-162 20 mg</title>
          <description>20 mg taken orally 30 minutes prior to bedtime</description>
        </group>
        <group group_id="P3">
          <title>VEC-162 50 mg</title>
          <description>50 mg taken orally 30 minutes prior to bedtime</description>
        </group>
        <group group_id="P4">
          <title>VEC-162 100 mg</title>
          <description>100 mg taken orally 30 minutes prior to bedtime</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="103"/>
                <participants group_id="P4" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="102"/>
                <participants group_id="P4" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation- No Drug Administered</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Modified Intent-to-Treat. A total of 411 subjects received treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Taken orally 30 minutes prior to bedtime.</description>
        </group>
        <group group_id="B2">
          <title>VEC-162 20 mg</title>
          <description>20 mg taken orally 30 minutes prior to bedtime.</description>
        </group>
        <group group_id="B3">
          <title>VEC-162 50 mg</title>
          <description>50 mg taken orally 30 minutes prior to bedtime.</description>
        </group>
        <group group_id="B4">
          <title>VEC-162 100 mg</title>
          <description>100 mg taken orally 30 minutes prior to bedtime.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="102"/>
            <count group_id="B4" value="106"/>
            <count group_id="B5" value="411"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.9" spread="7.28"/>
                    <measurement group_id="B2" value="30.8" spread="8.41"/>
                    <measurement group_id="B3" value="31.0" spread="8.51"/>
                    <measurement group_id="B4" value="31.2" spread="8.19"/>
                    <measurement group_id="B5" value="31.0" spread="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="73"/>
                    <measurement group_id="B5" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Improvement of Latency to Persistent Sleep (LPS)</title>
        <description>The average improvement in Latency to persistent sleep (the number of minutes between Lights Off and the onset of at least 10 minutes of persistent sleep, as measured by polysomnography) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.</description>
        <time_frame>Night 1</time_frame>
        <population>Modified ITT defined as any subject randomized into the study who received a dose of study drug and had PSG data. For the purposes of this trial, a subject was considered to have PSG data if 50% or more of the full night PSG was scored.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Taken orally 30 minutes prior to bedtime.</description>
          </group>
          <group group_id="O2">
            <title>VEC-162 20 mg</title>
            <description>20 mg taken orally 30 minutes prior to bedtime.</description>
          </group>
          <group group_id="O3">
            <title>VEC-162 50 mg</title>
            <description>50 mg taken orally 30 minutes prior to bedtime.</description>
          </group>
          <group group_id="O4">
            <title>VEC-162 100 mg</title>
            <description>100 mg taken orally 30 minutes prior to bedtime.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Improvement of Latency to Persistent Sleep (LPS)</title>
          <description>The average improvement in Latency to persistent sleep (the number of minutes between Lights Off and the onset of at least 10 minutes of persistent sleep, as measured by polysomnography) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.</description>
          <population>Modified ITT defined as any subject randomized into the study who received a dose of study drug and had PSG data. For the purposes of this trial, a subject was considered to have PSG data if 50% or more of the full night PSG was scored.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8" spread="4.28"/>
                    <measurement group_id="O2" value="24.3" spread="4.35"/>
                    <measurement group_id="O3" value="19.6" spread="4.31"/>
                    <measurement group_id="O4" value="23.1" spread="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-21.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.1</ci_lower_limit>
            <ci_upper_limit>-9.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-26.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.8</ci_lower_limit>
            <ci_upper_limit>-14.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-22.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.2</ci_lower_limit>
            <ci_upper_limit>-11.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Improvement of Wake After Sleep Onset (WASO)</title>
        <description>The average improvement of wake after sleep onset (time spent awake between onset of sleep and lights on, determined by PSG) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.</description>
        <time_frame>Night 1</time_frame>
        <population>Modified ITT defined as any subject randomized into the study who received a dose of study drug and had PSG data. For the purposes of this trial, a subject was considered to have PSG data if 50% or more of the full night PSG was scored.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Taken orally 30 minutes prior to bedtime.</description>
          </group>
          <group group_id="O2">
            <title>VEC-162 20 mg</title>
            <description>20 mg taken orally 30 minutes prior to bedtime</description>
          </group>
          <group group_id="O3">
            <title>VEC-162 50 mg</title>
            <description>50 mg taken orally 30 minutes prior to bedtime</description>
          </group>
          <group group_id="O4">
            <title>VEC-162 100 mg</title>
            <description>100 mg taken orally 30 minutes prior to bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Average Improvement of Wake After Sleep Onset (WASO)</title>
          <description>The average improvement of wake after sleep onset (time spent awake between onset of sleep and lights on, determined by PSG) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.</description>
          <population>Modified ITT defined as any subject randomized into the study who received a dose of study drug and had PSG data. For the purposes of this trial, a subject was considered to have PSG data if 50% or more of the full night PSG was scored.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.3" spread="7.33"/>
                    <measurement group_id="O2" value="115.1" spread="7.46"/>
                    <measurement group_id="O3" value="105.6" spread="7.39"/>
                    <measurement group_id="O4" value="121.9" spread="7.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-24.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.1</ci_lower_limit>
            <ci_upper_limit>-4.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-33.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.6</ci_lower_limit>
            <ci_upper_limit>-13.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.081</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.0</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Average Improvement in Total Sleep Time (TST)</title>
        <description>The average improvement in Total sleep time (determined by PSG and defined as the number of non-wake minutes between lights off and lights on) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.</description>
        <time_frame>Night 1</time_frame>
        <population>Modified ITT defined as any subject randomized into the study who received a dose of study drug and had PSG data. For the purposes of this trial, a subject was considered to have PSG data if 50% or more of the full night PSG was scored.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Taken orally 30 minutes prior to bedtime.</description>
          </group>
          <group group_id="O2">
            <title>VEC-162 20 mg</title>
            <description>20 mg taken orally 30 minutes prior to bedtime.</description>
          </group>
          <group group_id="O3">
            <title>VEC-162 50 mg</title>
            <description>50 mg taken orally 30 minutes prior to bedtime.</description>
          </group>
          <group group_id="O4">
            <title>VEC-162 100 mg</title>
            <description>100 mg taken orally 30 minutes prior to bedtime.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Improvement in Total Sleep Time (TST)</title>
          <description>The average improvement in Total sleep time (determined by PSG and defined as the number of non-wake minutes between lights off and lights on) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.</description>
          <population>Modified ITT defined as any subject randomized into the study who received a dose of study drug and had PSG data. For the purposes of this trial, a subject was considered to have PSG data if 50% or more of the full night PSG was scored.</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317.6" spread="7.65"/>
                    <measurement group_id="O2" value="351.4" spread="7.78"/>
                    <measurement group_id="O3" value="365.5" spread="7.71"/>
                    <measurement group_id="O4" value="347.2" spread="7.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>33.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.0</ci_lower_limit>
            <ci_upper_limit>54.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>47.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.2</ci_lower_limit>
            <ci_upper_limit>68.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>29.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.1</ci_lower_limit>
            <ci_upper_limit>50.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Average Improvement in Latency to Non-awake (LNA)</title>
        <description>The average improvement in latency to non-awake (length of time elapsed between lights off and first epoch of sleep determined by PSG) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.</description>
        <time_frame>Night 1</time_frame>
        <population>Modified ITT defined as any subject randomized into the study who received a dose of study drug and had PSG data. For the purposes of this trial, a subject was considered to have PSG data if 50% or more of the full night PSG was scored.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Taken orally 30 minutes prior to bedtime</description>
          </group>
          <group group_id="O2">
            <title>VEC-162 20 mg</title>
            <description>20 mg taken orally 30 minutes prior to bedtime.</description>
          </group>
          <group group_id="O3">
            <title>VEC-162 50 mg</title>
            <description>50 mg taken orally 30 minutes prior to bedtime.</description>
          </group>
          <group group_id="O4">
            <title>VEC-162 100 mg</title>
            <description>100 mg taken orally 30 minutes prior to bedtime.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Improvement in Latency to Non-awake (LNA)</title>
          <description>The average improvement in latency to non-awake (length of time elapsed between lights off and first epoch of sleep determined by PSG) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.</description>
          <population>Modified ITT defined as any subject randomized into the study who received a dose of study drug and had PSG data. For the purposes of this trial, a subject was considered to have PSG data if 50% or more of the full night PSG was scored.</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" spread="2.88"/>
                    <measurement group_id="O2" value="11.2" spread="2.93"/>
                    <measurement group_id="O3" value="8.0" spread="2.90"/>
                    <measurement group_id="O4" value="10.0" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.9</ci_lower_limit>
            <ci_upper_limit>-3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.1</ci_lower_limit>
            <ci_upper_limit>-6.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.0</ci_lower_limit>
            <ci_upper_limit>-4.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 through Day 2.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Taken orally 30 minutes prior to bedtime.</description>
        </group>
        <group group_id="E2">
          <title>VEC-162 20 mg</title>
          <description>20 mg taken orally 30 minutes prior to bedtime.</description>
        </group>
        <group group_id="E3">
          <title>VEC-162 50 mg</title>
          <description>50 mg taken orally 30 minutes prior to bedtime.</description>
        </group>
        <group group_id="E4">
          <title>VEC-162 100 mg</title>
          <description>100 mg taken orally 30 minutes prior to bedtime.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Dreams</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marlene Dressman, PhD.</name_or_title>
      <organization>Vanda Pharmaceuticals Inc.</organization>
      <phone>202-734-3462</phone>
      <email>marlene.dressman@vandapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

